Title : Serum albumin level interferes with the effect of Donepezil in Alzheimer's disease - Rozzini_2008_Aging.Clin.Exp.Res_20_509 |
Author(s) : Rozzini L , Vicini Chilovi B , Bertoletti E , Ghianda D , Conti M , Trabucchi M , Padovani A |
Ref : Aging Clin Exp Res , 20 :509 , 2008 |
Abstract :
BACKGROUND AND AIMS:
The most successful therapeutic approaches to Alzheimer's disease (AD) have involved acetylcholinesterase inhibitors (ChEIs). In view of the different response rates to ChEIs therapy, it is important to identify the pharmacokinetic and pharmacodynamic mechanisms which may interfere with this effect. The aim of the study is to evaluate the efficacy on cognition of donepezil, a cholinesterase inhibitor, in a sample of mild to moderate AD patients with various serum albumin levels, a condition modifying drug distribution.
|
PubMedSearch : Rozzini_2008_Aging.Clin.Exp.Res_20_509 |
PubMedID: 19179833 |
Rozzini L, Vicini Chilovi B, Bertoletti E, Ghianda D, Conti M, Trabucchi M, Padovani A (2008)
Serum albumin level interferes with the effect of Donepezil in Alzheimer's disease
Aging Clin Exp Res
20 :509
Rozzini L, Vicini Chilovi B, Bertoletti E, Ghianda D, Conti M, Trabucchi M, Padovani A (2008)
Aging Clin Exp Res
20 :509